Management of Androgen-Independent Prostate Cancer

Jemal A. , Tiwari R.C. , Murray T. Cancer statistics, 2004. CA Cancer J Clin. 2004; 54: 8–29.

Goktas S. , Crawford E.D. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol. 1999; 26: 162–173.

Oh W.K. , Kantoff P.W. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol. 1998; 160: 1220–1229.

Hussain M. , Wolf M. , Marshall E. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol. 1994; 12: 1868–1875.

Smaletz O. , Kelley W.K. , Verbel D.A. A nomogram for overall survival of patients with castrate-metastatic prostate cancer (PC). Proc Annu Meet Am Soc Clin Oncol. 2001; 728. Abstract.

Small E.J. , Picus J. , Chen Y. A prospective randomized trial of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in androgen independent prostate cancer patients: results of CALGB 9583. Proc Annu Meet Am Soc Clin Oncol. 2001; 695. Abstract.

Yagoda A. , Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993; 71: 1098–1109.

Tannock I.F. , Osoba D. , Stockler M.R. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996; 14: 1756–1764.

Greene F.L. , Page D.L. , Fleming I.D. , eds. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.

Crawford E.D. , Blumenstein B.A. Proposed substages for metastatic prostate cancer. Urology. 1997; 50: 1027–1028.

Isaacs J.T. , Coffey D.S. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res. 1981; 41: 5070–5075.

Newling D. , Fossa S.D. , Anderson L. Assessment of hormone refractory prostate cancer. Urology. 1997; 49(4A suppl): 46–53.

Scher H.I. , Steineck G. , Kelly W.K. Hormone-refractory (D3) prostate cancer: refining the concept. Urology. 1995; 46: 142–148.

Dawson N.A. Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials. J Clin Oncol. 1998; 16: 3398–3405.

Kantoff P.W. , Halabi S. , Conaway M. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999; 17: 2506–2513.

Oh W.K. Secondary hormonal therapies in the treatment of prostate cancer. Urology. 2002; 60(3 suppl 1): 87–92; discussion 93.

Kelly W.K. , Scher H.I. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993; 149: 607–609.

Scher H.I. , Liebertz C. , Kelly W.K. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol. 1997; 15: 2928–2938.

Kucuk O. , Fisher E. , Noinpour C.M. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology. 2001; 58: 53–58.

Joyce R. , Fenton M.A. , Rode P. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol. 1998; 159: 149–153.

Dawson N.A. , Conaway M. , Halabi S. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: Cancer and Leukemia Group B study 9181. Cancer. 2000; 88: 825–834.

Sandow J. , von Rechenberg W. , Engelbart K. Pharmacological studies on androgen suppression in therapy of prostate carcinoma. Am J Clin Oncol. 1988; 11(suppl 1): S6–S10.

Geller J. , Albert J. , Vik A. Advantages of total androgen blockade in the treatment of advanced prostate cancer. Semin Oncol. 1988; 15(2 suppl 1): 53–61.

Moore M.J. Quality of life in advanced prostate cancer. Can J Urol. 1997; 4(2 suppl 1): 71–73.

Nishimura K. , Nonomura N. , Yasunaga Y. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer. 2000; 89: 2570–2576.

Kantoff P.W. , Halabi S. , Conaway M. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol. 1999; 17: 2506–2513.

Dawson N.A. Treatment of progressive metastatic prostate cancer. Oncology (Huntingt). 1993; 7: 17–24, 27; discussion 27-29. Published erratum of serious dosage error appears in Oncology (Huntingt). 1993; 7: 2.

Small E.J. , Baron A.D. , Fippin L. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol. 1997; 157: 1204–1207.

Millikan R. , Baez L. , Banerjee T. Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urol Oncol. 2001; 6: 111–115.

Small E.J. , Picus J. , Chen Y. A prospective randomized trial of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in androgen independent prostate cancer patients: results of CALGB 9583. Proc Annu Meet Am Soc Clin Oncol. 2001; 695. Abstract.

Harris K. , Small E.J. , Frohlich M.W. Prospective trial of low dose ketoconazole (LDK) therapy in patients (Pts) with androgen independent prostate cancer (AIPC). Proc Annu Meet Am Soc Clin Oncol. 2001; 20: 2419.

Robertson C.N. , Roberson K.M. , Padilla G.M. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst. 1996; 88: 908–917.

Shahidi M. , Norman A.R. , Gadd J. Prospective review of diethylstilbestrol in advanced prostate cancer no longer responding to androgen suppression. Proc Annu Meet Am Soc Clin Oncol. 2001; 2455. Abstract.

Smith D.C. , Redman B.G. , Flaherty L.E. A phase II trial of oral diethylstilbestrol as a second-line hormonal agent in advanced prostate cancer. Urology. 1998; 52: 257–260.

Rosenbaum E. , Wygoda M. , Gips M. Diethylstilbestrol is an active agent in prostatic cancer patients after failure to complete androgen blockade. Proc Annu Meet Am Soc Clin Oncol. 2000; 349. Abstract.

Oh W.K. , George D.J. , Hackmann K. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology. 2001; 57: 122–126.

Pfeifer B.L. , Pirani J.F. , Hamann S.R. PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int. 2000; 85: 481–485.

Kubota T. , Hisatake J. , Hisatake Y. PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo. Prostate. 2000; 42: 163–171.

DiPaola R.S. , Zhang H. , Lambert G.H. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med. 1998; 339: 785–791.

Ades T. , Gansler T. , Miller M. PC-SPES: current evidence and remaining questions. CA Cancer J Clin. 2001; 51: 199–204.

Oh W.K. , Kantoff P.W. , Weinberg V. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol. 2004; 22: 3705–3712.

Sharifi R. , Soloway M. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer: the Leuprolide Study Group. J Urol. 1990; 143: 68–71.

Fowler J.E. Jr , Whitmore W.F. Jr . The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol. 1981; 126: 372–375.

Taylor C.D. , Elson P. , Trump D.L. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol. 1993; 11: 2167–2172.

Kelly W.K. , Scher H.I. , Mazumdar M. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1993; 11: 607–615.

Bubley G.J. , Carducci M. , Dahut W. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999; 17: 3461–3467.

Raghavan D. , Cox K. , Pearson B.S. Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol. 1993; 72: 625–628.

von Roemeling R. , Fisher H.A.G. , Horton J. Daily oral cyclophosphamide is effective in hormone refractory prostate cancer: a phase I/II pilot study. Proc Annu Meet Am Soc Clin Oncol. 1992; 213. Abstract.

Ukimura O. , Kamoi K. , Hongo F. Oral administration of dexamethasone in combination with UFT and cyclophosphamide for the treatment of hormone-refractory prostate cancer. Proc Annu Meet Am Soc Clin Oncol. 2001; 2412. Abstract.

Maulard-Durdux C. , Dufour B. , Hennequin C. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer. 1996; 77: 1144–1148.

Wozniak A.J. , Blumenstein B.A. , Crawford E.D. Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer: a Southwest Oncology Group study. Cancer. 1993; 71: 3975–3978.

Varkarakis M.J. , Kirdani R.Y. , Murphy G.P. Antiprostatic effects of a nitrogen mustard of estriol. Proc Soc Exp Biol Med. 1975; 148: 904–908.

Hartley-Asp B. , Kruse E. Nuclear protein matrix as a target for estramustine-induced cell death. Prostate. 1986; 9: 387–395.

Pienta K.J. , Lehr J.E. Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol. 1993; 149: 1622–1625.

Attivissimo L.A. , Fetten J.V. , Kreis W. Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer. Am J Clin Oncol. 1996; 19: 581–583.

Hudes G.R. , Greenberg R. , Krigel R.L. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol. 1992; 10: 1754–1761.

Petrylak D.P. , Macarthur R.B. , O'Connor J. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999; 17: 958–967.

Hudes G.R. , Nathan F.E. , Khater C. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol. 1995; 22(5 suppl 12): 41–45.

Mareel M.M. , Storme G.A. , Dragonetti D.M. Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro. Cancer Res. 1988; 48: 1842–1849.

Pienta K.J. , Redman B. , Hussain M. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol. 1994; 12: 2005–2012.

Hudes G.R. , Nathan F. , Khater C. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1997; 15: 3156–3163.

Tiersten A.D. , Nelson C. , Talbot S. A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer. 2003; 97: 537–544.

Oudard S. , Caty A. , Humblet Y. Phase II study of vinorelbine in patients with androgen-independent prostate cancer. Ann Oncol. 2001; 12: 847–852.

Hudes G. , Einhorn L. , Ross E. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol. 1999; 17: 3160–3166.

Hudes G. , Einhorn L. , Ross E. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. Classic Papers and Current Comments. 2001; 6: 318–325.

Horwitz S.B. Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994; 5(suppl 6): S3–S6.

Ringel I. , Horwitz S.B. Studies with RP 56976 (taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst. 1991; 83: 288–291.

Diaz J.F. , Andreu J.M. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry. 1993; 32: 2747–2755.

Berry W. , Dakhil S. , Gregurich M.A. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol. 2001; 28: 8–15.

Sitka Copur M. , Ledakis P. , Lynch J. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol. 2001; 28(4 suppl 15): 16–21.

Urakami S. , Igawa M. , Kikuno N. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol. 2002; 168: 2444–2450.

Smith D.C. , Esper P. , Strawderman M. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol. 1999; 17: 1664–1671.

Savarese D.M. , Halabi S. , Hars V. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol. 2001; 19: 2509–2616.

Kelly W.K. , Curley T. , Slovin S. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol. 2001; 19: 44–53.

Beer T.M. , Eilers K.M. , Garzotto M. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 2003; 21: 123–128.

Tannock I.F. , deWit R. , Berry W.J. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502–1512.

Petrylak D.P. , Tangen C.M. , Hussain M.H. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513–1520.

Figg W.D. , Arlen P. , Gulley J. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol. 2001; 28(4 suppl 15): 62–66.

Beer T.M. , Hough K.M. , Garzotto M. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol. 2001; 28(4 suppl 15): 49–55.

Hershberger P.A. , Yu W.D. , Modzelewski R.A. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res. 2001; 7: 1043–1051.

Therasse P. , Arbuck S.G. , Eisenhauer E.A. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205–216.

Nelson J.B. , Hedican S.P. , George D.J. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995; 1: 944–949.

Nelson J. , Bagnato A. , Battistine B. The endothelin axis: emerging role in cancer. Nature. 2003; 3: 110–116.

Wu-Wong J.R. Endothelin receptor antagonists: past, present and future. Curr Opin Cardiovasc Pulmon Renal Invest Drugs. 1999; 1: 346–351.

Gohji K. , Kitazawa S. , Tamada H. Expression of endothelin receptor a associated with prostate cancer progression. J Urol. 2001; 165: 1033–1036.

Opgenorth T.J. , Adler A.L. , Calzadilla S.V. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther. 1996; 276: 473–481.

Carducci M.A. , Padley R.J. , Brail J. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003; 21: 679–689.

Diamond T. , Campbell J. , Bryant C. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer. 1998; 83: 1561–1566.

Smith M.R. , Eastham J. , Gleason D.M. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003; 169: 2008–2012.

Smith M.R. , McGovern J.P. , Zietman A.L. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001; 345: 948–955.

Hortobagyi G.N. , Theriault R.L. , Porter L. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996; 335: 1785–1791.

Theriault R.L. , Lipton A. , Hortobagyi G.N. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999; 17: 846–854.

Pavlakis N. , Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2002. CD003474.

Djulbegovic B. , Wheatley K. , Ross J. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev. 2002. CD003188.

Saad F. , Gleason D.M. , Murray R. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94: 1458–1468.